AR121355A1 - Compuestos antivirales - Google Patents

Compuestos antivirales

Info

Publication number
AR121355A1
AR121355A1 ARP210100408A ARP210100408A AR121355A1 AR 121355 A1 AR121355 A1 AR 121355A1 AR P210100408 A ARP210100408 A AR P210100408A AR P210100408 A ARP210100408 A AR P210100408A AR 121355 A1 AR121355 A1 AR 121355A1
Authority
AR
Argentina
Prior art keywords
independently
alkyl
optionally substituted
membered heterocyclyl
alkoxy
Prior art date
Application number
ARP210100408A
Other languages
English (en)
Inventor
Gregory F Chin
Byoung Chun
- Clarke Michael Oneil Hanrahan Kwon
Bindu Goyal
Hon C Hui
Petr Jansa
Richard L Mackman
Dustin S Siegel
Hai Yang
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of AR121355A1 publication Critical patent/AR121355A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente divulgación proporciona compuestos para tratar una variedad de enfermedades, tales como virus respiratorio sincitial (RSV), HRV, hMPV, Ébola, Zika, virus del Nilo Occidental, Dengue y VHC. Reivindicación 1: Un compuesto de fórmula (1) o una sal farmacéuticamente aceptable del mismo, en donde: Base es un compuesto del grupo de fórmulas (2); R¹A y R²A son cada uno independientemente: (A) alquilo C₁₋₁₂ opcionalmente sustituido con 1 a 3 R¹B, (B) heterociclilo de 3 a 6 miembros que tiene de 1 a 3 heteroátomos seleccionados independientemente de N, O y S, en donde el heterociclilo de 3 a 6 miembros es opcionalmente sustituido con 1 a 3 R¹C, o (C) fenilo, en donde cada R¹B es independientemente -OH, -NH₂, alcoxi C₁₋₆, metoxietoxi, o heterociclilo de 3 a 6 miembros que tiene de 1 a 3 heteroátomos seleccionados independientemente de N, O y S, y cada R¹C es independientemente alquilo C₁₋₃; R³ es -N(H)R³A o -N=C(R³B)(R³C); R³A es H, -CH₂OP(O)(OH)₂, o -C(O)R³D, en donde R³D es alquilo C₁₋₆ opcionalmente sustituido con 1 metoxi, o heterociclilo de 3 a 6 miembros que tiene de 1 a 3 heteroátomos seleccionados independientemente de N, O y S, opcionalmente sustituido con alquilo C₁₋₃; R³B es H o alquilo C₁₋₃; R³C es -N(R³C¹)(R³C²); R³C¹ y R³C² son cada uno independientemente H o alquilo C₁₋₆; o R³C¹ y R³C² junto con el átomo a que están unidos forman un heterociclilo de 3 a 6 miembros que tiene de 1 a 3 heteroátomos seleccionados independientemente de N, O y S, opcionalmente sustituido con alquilo C₁₋₆; R⁴A es O ó S; y R⁴B y R⁴C son cada uno independientemente (A) -OH; (B) -OR⁴B¹, en donde R⁴B¹ es alquilo C₁₋₆ opcionalmente sustituido con 1 a 3 grupos R⁴B², o arilo C₆₋₁₂, en donde cada grupo R⁴B² es independientemente alcoxi C₁₋₆, -S-R⁴B³, o -S(O)₂-R⁴B³, y cada grupo R⁴B³ es independientemente alquilo C₁₋₆; (C) un compuesto de fórmula (3), en donde m es 0, 1, 2, 3, 4, ó 5; y cada R⁴D es independientemente alquilo C₁₋₃ opcionalmente sustituido con 1 a 3 grupos R⁴D¹, alcoxi C₁₋₃ opcionalmente sustituido con 1 a 3 grupos R⁴D², o -C(O)N(R⁴D³)₂, en donde cada grupo R⁴D¹ es independientemente -NH₂ o -C(O)OR⁴D³, cada R⁴D² es independientemente alcoxi C₁₋₃, y cada R⁴D³ es independientemente alquilo C₁₋₃; (D) un compuesto de fórmula (4), en donde R⁴E¹ y R⁴E² son cada uno independientemente H o alquilo C₁₋₆, R⁴F¹ y R⁴F² son cada uno independientemente H o alquilo C₁₋₆, o R⁴F¹ y R⁴F² juntos son oxo, R⁴G es alquilo C₁₋₁₂ opcionalmente sustituido con 1 a 3 R⁴G¹, cicloalquilo C₃₋₇ opcionalmente sustituido con 1 a 3 R⁴G², heterociclilo de 3 a 8 miembros que tiene 1 a 3 heteroátomos seleccionados de N, O y S, opcionalmente sustituido con 1 a 3 R⁴G³, o -C(O)R⁴G⁴, cada R⁴G¹ es independientemente -OH, alquilo C₁₋₆, alcoxi C₁₋₃, -(CH₂OCH₂)₁₋₅-CH₃, -N(R⁴G⁸)₂, -OP(O)(OH)₂, cicloalquilo C₃₋₇ opcionalmente sustituido con 1 a 3 R⁴G⁹, heterociclilo de 3 a 6 miembros que tiene de 1 a 3 heteroátomos seleccionados independientemente de N, O y S, opcionalmente sustituido con 1 a 3 R⁴G¹⁰, o fenilo, cada R⁴G² es independientemente alquilo C₁₋₆, haloalquilo C₁₋₃, o -NH₂, cada R⁴G³ es independientemente halógeno o alquilo C₁₋₃; cada R⁴G⁴ es independientemente alquilo C₁₋₁₂, cada R⁴G⁸ es independientemente alquilo C₁₋₆, cada R⁴G⁹ es independientemente haloalquilo C₁₋₃, o -NH₂, y cada R⁴G¹⁰ es independientemente haloalquilo C₁₋₃; o (E) -(OP(O)(OH))₁₋₂-OH; y R⁵A y R⁵B son cada uno alquilo C₁₋₆ sustituido con -OP(O)(OH)₂.
ARP210100408A 2020-02-18 2021-02-17 Compuestos antivirales AR121355A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202062977881P 2020-02-18 2020-02-18

Publications (1)

Publication Number Publication Date
AR121355A1 true AR121355A1 (es) 2022-05-11

Family

ID=74859527

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210100408A AR121355A1 (es) 2020-02-18 2021-02-17 Compuestos antivirales

Country Status (10)

Country Link
US (2) US11767337B2 (es)
EP (1) EP4107164A1 (es)
JP (2) JP7483023B2 (es)
KR (1) KR20220142483A (es)
CN (1) CN115087659A (es)
AR (1) AR121355A1 (es)
AU (2) AU2021221986B2 (es)
CA (1) CA3171497A1 (es)
TW (2) TWI794742B (es)
WO (1) WO2021168038A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118598916A (zh) 2020-02-18 2024-09-06 吉利德科学公司 抗病毒化合物
TW202245800A (zh) 2020-02-18 2022-12-01 美商基利科學股份有限公司 抗病毒化合物
WO2022166581A1 (zh) * 2021-02-07 2022-08-11 石家庄迪斯凯威医药科技有限公司 一种核苷酸衍生物及其药物组合物和用途
US11697666B2 (en) 2021-04-16 2023-07-11 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
CA3228162A1 (en) 2021-08-18 2023-02-23 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
CN115947758A (zh) * 2021-10-07 2023-04-11 南京知和医药科技有限公司 一种核苷酸衍生物及其药物组合物和用途
IL314961A (en) * 2022-03-03 2024-10-01 Gilead Sciences Inc Antiviral compounds and methods for their production and use
WO2023168254A1 (en) * 2022-03-03 2023-09-07 Gilead Sciences, Inc. Antiviral compounds and methods of making and using the same

Family Cites Families (485)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3361306A (en) 1966-03-31 1968-01-02 Merck & Co Inc Aerosol unit dispensing uniform amounts of a medically active ingredient
US3565070A (en) 1969-02-28 1971-02-23 Riker Laboratories Inc Inhalation actuable aerosol dispenser
FR2224175B1 (es) 1973-04-04 1978-04-14 Isf Spa
US4069819A (en) 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
IT1017153B (it) 1974-07-15 1977-07-20 Isf Spa Apparecchio per inalazioni
NL7606413A (en) 1976-06-14 1977-12-16 Kowa Co Adenosine-5'-phosphoric acid derivs. and their salts - prepd. by acylating adenosine-5'-phosphate and opt. desalting or salt exchanging
DE2626792A1 (de) 1976-06-15 1977-12-29 Kowa Co Acylderivate von adenosin-5'-monophosphorsaeure, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzung
FR2354774A1 (fr) 1976-06-15 1978-01-13 Kowa Co Derives de l'acide adenosine-5'-monophosphorique et medicament contenant ces substances
SE438261B (sv) 1981-07-08 1985-04-15 Draco Ab Anvendning i dosinhalator av ett perforerat membran
US4805811A (en) 1985-03-29 1989-02-21 Aktiebolaget Draco Dosage device
SE448277B (sv) 1985-04-12 1987-02-09 Draco Ab Indikeringsanordning vid en doseringsanordning for lekemedel
JPS6286363A (ja) 1985-10-11 1987-04-20 Fuji Photo Film Co Ltd ハロゲン化銀カラ−写真感光材料
DE3528753A1 (de) 1985-08-10 1987-02-19 Bayer Ag Substituierte pyrazolin-5-one
US4707540A (en) 1986-10-29 1987-11-17 Morton Thiokol, Inc. Nitramine oxetanes and polyethers formed therefrom
US4871758A (en) 1987-03-18 1989-10-03 Schulman Jerome M Pharmacologically active cholinergic compositions, and methods for making same and use thereof in treating disease
DE3711345A1 (de) 1987-04-03 1988-10-20 Bayer Ag Substituierte propylamine
IN167775B (es) 1988-06-24 1990-12-22 Hoechst India
IT1228459B (it) 1989-02-23 1991-06-19 Phidea S R L Inalatore con svuotamento regolare e completo della capsula.
US4955371A (en) 1989-05-08 1990-09-11 Transtech Scientific, Inc. Disposable inhalation activated, aerosol device for pulmonary medicine
US5674998A (en) 1989-09-15 1997-10-07 Gensia Inc. C-4' modified adenosine kinase inhibitors
DE3932052A1 (de) 1989-09-26 1991-04-04 Basf Ag Oxazol- bzw. thiazolcarbonsaeureamide
CA2073500C (en) 1990-01-11 2008-03-25 Phillip Dan Cook Compositions and methods for detecting and modulating rna activity and gene expression
YU84791A (sh) 1990-05-19 1994-06-10 Boehringer Ingelheim Kg. Biciklicni 1-aza-cikloalkalni
MY106399A (en) 1990-07-24 1995-05-30 Pfizer Cephalosporins and homologeus, preparation and pharmaceutical composition
FR2669639A1 (fr) 1990-11-27 1992-05-29 Atochem Cocatalyseur de polymerisation du propylene a base de silane et de monoether.
TW239158B (es) 1991-02-15 1995-01-21 Lubrizol Corp
JP3230056B2 (ja) 1991-07-02 2001-11-19 インヘイル・インコーポレーテッド 薬剤のエーロゾル化服用量を形成する装置
GB9202791D0 (en) 1992-02-11 1992-03-25 British Bio Technology Compounds
US5261538A (en) 1992-04-21 1993-11-16 Glaxo Inc. Aerosol testing method
US5785049A (en) 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
DE4232852A1 (de) 1992-09-30 1994-03-31 Bayer Ag Imidazolinyl-pyridazine
US5388572A (en) 1993-10-26 1995-02-14 Tenax Corporation (A Connecticut Corp.) Dry powder medicament inhalator having an inhalation-activated piston to aerosolize dose and deliver same
US5446137B1 (en) 1993-12-09 1998-10-06 Behringwerke Ag Oligonucleotides containing 4'-substituted nucleotides
DE69522494T2 (de) 1994-04-14 2002-04-25 Canon K.K., Tokio/Tokyo Flüssigkristallzusammensetzung, Anzeigevorrichtung und Verfahren diese verwendend
US5522385A (en) 1994-09-27 1996-06-04 Aradigm Corporation Dynamic particle size control for aerosolized drug delivery
US5681940A (en) 1994-11-02 1997-10-28 Icn Pharmaceuticals Sugar modified nucleosides and oligonucleotides
US5544647A (en) 1994-11-29 1996-08-13 Iep Group, Inc. Metered dose inhalator
US5622163A (en) 1994-11-29 1997-04-22 Iep Group, Inc. Counter for fluid dispensers
JP3822925B2 (ja) 1995-07-18 2006-09-20 興和株式会社 2’−3’−ジ−o−アシルatpの製造法
JPH09328497A (ja) 1996-04-12 1997-12-22 Yamasa Shoyu Co Ltd 4’−フルオロメチルヌクレオシド
CN1233254A (zh) 1996-10-16 1999-10-27 Icn药品公司 嘌呤l-核苷、其类似物及其用途
EP1000075A4 (en) 1997-06-30 2001-09-05 Icn Pharmaceuticals PROCESS FOR PRODUCING TIAZOFURINE AND OTHER C-NUCLEOSIDES
EP2341058A3 (en) 1997-09-12 2011-11-23 Exiqon A/S Oligonucleotide Analogues
AU1608399A (en) 1997-11-26 1999-06-15 Axys Pharmaceuticals, Inc. Substituted amidinoaryl derivatives and their use as anticoagulants
US6150379A (en) 1997-11-26 2000-11-21 Axys Pharmaceuticals, Inc. Compounds and compositions as anticoagulants
US5972099A (en) 1997-12-17 1999-10-26 Bayer Corporation Process for preparing organic pigment compositions
PE20000354A1 (es) 1998-04-03 2000-05-20 Advanced Medicine Inc Nuevos compuestos y usos anestesicos locales
WO1999061583A2 (en) 1998-05-28 1999-12-02 Incara Pharmaceuticals Corp. Carbohydrate-based scaffold compounds, combinatorial libraries and methods for their construction
EP1094805A4 (en) 1998-07-03 2002-08-28 Millennium Pharm Inc ALICYCLIC COMPOUNDS WITH SUBSTITUTED OXYGEN ATOM, AND THEIR PREPARATION METHOD
AU1933800A (en) 1998-12-02 2000-06-19 Princeton University Compositions and methods for regulating bacterial pathogenesis
US6432975B1 (en) 1998-12-11 2002-08-13 Targacept, Inc. Pharmaceutical compositions and methods for use
US6116234A (en) 1999-02-01 2000-09-12 Iep Pharmaceutical Devices Inc. Metered dose inhaler agitator
EP1046631A1 (en) 1999-04-19 2000-10-25 Rolic AG Liquid crystalline compounds
GB9908934D0 (en) 1999-04-19 1999-06-16 Rolic Ag Liquid crystalline compounds
US7053207B2 (en) 1999-05-04 2006-05-30 Exiqon A/S L-ribo-LNA analogues
AUPQ105499A0 (en) 1999-06-18 1999-07-08 Biota Scientific Management Pty Ltd Antiviral agents
AU5780800A (en) 1999-06-29 2001-01-31 Uab Research Foundation, The Methods of treating fungal infections with inhibitors of nad synthetase enzyme
DE19934799B4 (de) 1999-07-28 2008-01-24 Az Electronic Materials (Germany) Gmbh Chiral-smektische Flüssigkristallmischung und ihre Verwendung in Aktivmatrix-Displays mit hohen Kontrastwerten
CA2381008A1 (en) 1999-08-04 2001-02-15 Millennium Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
DE19939910A1 (de) 1999-08-23 2001-03-01 Morphochem Ag Neue Verbindungen, die Tryptase-Aktivität hemmen
EP1214332A1 (en) 1999-09-17 2002-06-19 Amersham Biosciences Corp. Charge-modified nucleic acid terminators
AU7315700A (en) 1999-09-20 2001-04-24 Takeda Chemical Industries Ltd. Melanin concentrating hormone antagonist
US6514964B1 (en) 1999-09-27 2003-02-04 Amgen Inc. Fused cycloheptane and fused azacycloheptane compounds and their methods of use
GB9930557D0 (en) 1999-12-23 2000-02-16 Rolic Ag Optically active materials
DK1259485T3 (da) 2000-02-29 2006-04-10 Millennium Pharm Inc Benzamider og beslægtede inhibitorer for faktor Xa
US20090124690A1 (en) 2000-04-03 2009-05-14 Alberte Randall S Generation of Combinatorial Synthetic Libraries and Screening for Novel Proadhesins and Nonadhesins
US6727267B2 (en) 2000-04-05 2004-04-27 Tularik Inc. NS5B HVC polymerase inhibitors
US6696081B2 (en) 2000-06-09 2004-02-24 Duke University Carbohydrate based lipid compositions and supramolecular structures comprising same
EP1170353B1 (en) 2000-07-06 2005-11-02 Fuji Photo Film Co., Ltd. Liquid crystal composition comprising liquid crystal molecules and aligment promoter
EP1301074A2 (en) 2000-07-14 2003-04-16 The UAB Research Foundation Uses for nad synthetase inhibitors
AU2001279955A1 (en) 2000-08-18 2002-03-04 Sterix Limited 2-substituted estradiol derivative for inhibiting superoxid dismutase
AU2001294865A1 (en) 2000-09-30 2002-04-15 Loctite Low shrinkage thermosetting resin compositions and methods of use therefor
NZ526003A (en) 2000-10-20 2005-09-30 Biocryst Pharm Inc Biaryl compounds as serine protease inhibitors
AUPR105700A0 (en) 2000-10-27 2000-11-23 Monash University Process for preparation of bicyclic and polycyclic molecules
WO2002039987A2 (en) 2000-11-14 2002-05-23 Neurosearch A/S Use of malaria parasite anion channel blockers for treating malaria
AUPR213700A0 (en) 2000-12-18 2001-01-25 Biota Scientific Management Pty Ltd Antiviral agents
DE10064823A1 (de) 2000-12-22 2002-06-27 Knoll Ag Integrinrezeptorliganden
WO2002062766A2 (en) 2001-02-07 2002-08-15 Millennium Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
JP2002326996A (ja) 2001-03-02 2002-11-15 Toray Ind Inc 光学活性体の製造法
JP4161291B2 (ja) 2001-03-02 2008-10-08 東レ・ファインケミカル株式会社 光学活性体の製造法
ATE438615T1 (de) 2001-04-06 2009-08-15 Biocryst Pharm Inc Biarylverbindungen als serinproteaseinhibitoren
EP2415486B1 (en) 2001-05-18 2017-02-22 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US20030175950A1 (en) 2001-05-29 2003-09-18 Mcswiggen James A. RNA interference mediated inhibition of HIV gene expression using short interfering RNA
US20030170891A1 (en) 2001-06-06 2003-09-11 Mcswiggen James A. RNA interference mediated inhibition of epidermal growth factor receptor gene expression using short interfering nucleic acid (siNA)
GB0114286D0 (en) 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
CA2458926A1 (en) 2001-09-13 2003-03-13 Genesoft Pharmaceuticals, Inc. Methods of treating infection by drug resistant bacteria
WO2003039523A2 (en) 2001-11-05 2003-05-15 Exiqon A/S OLIGONUCLEOTIDES MODIFIED WITH NOVEL α-L-RNA ANALOGUES
EP1446115B1 (en) 2001-11-13 2008-02-27 Merck Frosst Canada Ltd. Cyanoalkylamino derivatives as protease inhibitors
US7169814B2 (en) 2001-12-11 2007-01-30 The Board Of Trustees Of The Leland Stanford Junior University Guanidinium transport reagents and conjugates
JP2003246770A (ja) 2002-02-25 2003-09-02 Toray Ind Inc 光学活性体の製造法
TW200403058A (en) 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
US6869904B2 (en) 2002-04-24 2005-03-22 Symyx Technologies, Inc. Bridged bi-aromatic ligands, catalysts, processes for polymerizing and polymers therefrom
CA2483253A1 (en) 2002-04-24 2003-11-06 Takeda Pharmaceutical Company Limited Use of compounds having ccr antagonism
PT1523489E (pt) 2002-06-28 2014-06-24 Centre Nat Rech Scient Profármacos de nucleósido modificado em 2' e 3' para tratamento de infecções por flaviridae
WO2004007472A1 (ja) 2002-07-10 2004-01-22 Ono Pharmaceutical Co., Ltd. Ccr4アンタゴニストおよびその医薬用途
AU2003259735A1 (en) 2002-08-08 2004-02-25 Sirna Therapeutics, Inc. Small-mer compositions and methods of use
AU2003274652A1 (en) 2002-10-23 2004-05-13 Obetherapy Biotechnology Compounds, compositions and methods for modulating fat metabolism
US20040229840A1 (en) 2002-10-29 2004-11-18 Balkrishen Bhat Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
US20040146941A1 (en) 2002-11-04 2004-07-29 Biliang Zhang Chemical encoding technology for combinatorial synthesis
US7329658B2 (en) 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7176210B2 (en) 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
TWI344955B (en) 2003-03-14 2011-07-11 Ono Pharmaceutical Co Heterocyclic rinf having nitrogen atom derivatives and medicament containing the derivatives as active ingredient
US7135469B2 (en) 2003-03-18 2006-11-14 Bristol Myers Squibb, Co. Linear chain substituted monocyclic and bicyclic derivatives as factor Xa inhibitors
GB0306430D0 (en) 2003-03-20 2003-04-23 Bp Chem Int Ltd Polymerisation and oligomerisation catalysts
ES2423800T3 (es) 2003-03-28 2013-09-24 Novartis Vaccines And Diagnostics, Inc. Uso de compuestos orgánicos para la inmunopotenciación
EP1613261A4 (en) 2003-04-09 2011-01-26 Novo Nordisk As INTRA-CELLULAR FORMATION OF PEPTIDE CONJUGATES
JP2004315613A (ja) 2003-04-14 2004-11-11 Fuji Photo Film Co Ltd セルロースアシレートフィルム、その製造方法、偏光板保護膜、液晶表示装置、及びハロゲン化銀写真感光材料
US7268133B2 (en) 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
BRPI0410348A (pt) 2003-05-14 2006-05-30 Torreypines Therapeutics Inc compostos e usos dos mesmos na modulação de amilóide-beta
US20040229839A1 (en) 2003-05-14 2004-11-18 Biocryst Pharmaceuticals, Inc. Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
WO2005020885A2 (en) 2003-05-21 2005-03-10 Isis Pharmaceuticals, Inc. Compositions and methods for the treatment of severe acute respiratory syndrome (sars)
WO2004106356A1 (en) 2003-05-27 2004-12-09 Syddansk Universitet Functionalized nucleotide derivatives
WO2005021568A2 (en) 2003-08-27 2005-03-10 Biota, Inc. Novel tricyclic nucleosides or nucleotides as therapeutic agents
EP1661889A4 (en) 2003-09-05 2009-08-05 Ono Pharmaceutical Co ANTAGONIST OF THE CHEMOKINE RECEPTOR AND ITS USE FOR MEDICAL PURPOSES
WO2005025515A2 (en) 2003-09-12 2005-03-24 California Institute Of Technology Proteasome pathway inhibitors and related methods
JP4231379B2 (ja) 2003-10-15 2009-02-25 富士フイルム株式会社 潤滑剤組成物
JPWO2005040135A1 (ja) 2003-10-24 2007-03-08 小野薬品工業株式会社 抗ストレス薬およびその医薬用途
EP1692110A1 (en) 2003-12-10 2006-08-23 MERCK PATENT GmbH Diacylhydrazine derivatives
WO2005093476A1 (en) 2004-03-25 2005-10-06 Fuji Photo Film Co., Ltd. Transparent film and optical compensatory film, polarizing plate and liquid-crystal display device employing it
JP2007530470A (ja) 2004-03-25 2007-11-01 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 液晶化合物、液晶媒体および液晶ディスプレイ
US7306631B2 (en) 2004-03-30 2007-12-11 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
EP1593713A1 (en) 2004-05-04 2005-11-09 Rolic AG Polymerizable dichromophoric dichroic azo dyes
GB0410604D0 (en) 2004-05-12 2004-06-16 Bp Chem Int Ltd Ethylene copolymers
BRPI0512049A (pt) * 2004-06-14 2008-02-06 Anacor Pharmaceuticals Inc usos antivirais de complexos de ácido borìnico
US8039674B2 (en) 2004-06-23 2011-10-18 Ono Pharmaceutical Co., Ltd. Compound having S1P receptor binding potency and use thereof
WO2006006490A1 (ja) 2004-07-08 2006-01-19 Ono Pharmaceutical Co., Ltd. スピロ化合物
GB0415879D0 (en) 2004-07-15 2004-08-18 Bp Chem Int Ltd Polymerisation catalyst
GB0418022D0 (en) 2004-08-12 2004-09-15 Bp Chem Int Ltd Polymerisation and oligomerisation catalyst
GB0420396D0 (en) 2004-09-14 2004-10-13 Bp Chem Int Ltd Polyolefins
WO2006038594A1 (ja) 2004-10-04 2006-04-13 Ono Pharmaceutical Co., Ltd. N型カルシウムチャネル阻害薬
GB0424422D0 (en) 2004-11-04 2004-12-08 Bp Chem Int Ltd Polymerisation catalysts
JP4429149B2 (ja) 2004-11-26 2010-03-10 キヤノン株式会社 フルオレン化合物及び有機発光素子
GB2436261B (en) 2004-12-11 2010-06-09 Merck Patent Gmbh Liquid crystal compounds,liquid crystal medium and liquid crystal display
WO2006066074A2 (en) 2004-12-16 2006-06-22 The Regents Of The University Of California Lung-targeted drugs
WO2006063717A2 (en) 2004-12-16 2006-06-22 Febit Biotech Gmbh Polymerase-independent analysis of the sequence of polynucleotides
JP4749000B2 (ja) 2005-02-22 2011-08-17 富士フイルム株式会社 グリース組成物
US7622240B2 (en) 2005-02-28 2009-11-24 International Business Machines Corporation Low blur molecular resist
US8802840B2 (en) 2005-03-08 2014-08-12 Biota Scientific Management Pty Ltd. Bicyclic nucleosides and nucleotides as therapeutic agents
DE602006016928D1 (de) 2005-03-15 2010-10-28 Fujifilm Corp Oberflächenbehandlungsverfahren unter verwendung einer scheibenartigen verbindung, (schmier)zusammensetzung zur oberflächenbehandlung und oberflächenbehandelter gegenstand
CA2610854A1 (en) 2005-03-30 2006-10-05 Sirtris Pharmaceuticals, Inc. Nicotinamide riboside and analogues thereof
US20090156545A1 (en) 2005-04-01 2009-06-18 Hostetler Karl Y Substituted Phosphate Esters of Nucleoside Phosphonates
US20070003608A1 (en) 2005-04-08 2007-01-04 Almond Merrick R Compounds, compositions and methods for the treatment of viral infections and other medical disorders
WO2006119800A1 (en) 2005-05-09 2006-11-16 Technische Universität Braunschweig Light emitting compound for electroluminescent applications
US7576205B2 (en) 2005-06-13 2009-08-18 Agency For Science, Technology & Research Detectable threading intercalator
WO2007007588A1 (ja) 2005-07-08 2007-01-18 Ono Pharmaceutical Co., Ltd. 平面性を有する環状基を母核とする化合物
WO2007011759A2 (en) 2005-07-15 2007-01-25 Kalypsys, Inc. Inhibitors of mitotic kinesin
JP2007056213A (ja) 2005-08-26 2007-03-08 Fujifilm Corp 焼結含油軸受油用組成物、並びにそれを用いた軸受け装置及び摺動部材
DE102005043165A1 (de) 2005-09-12 2007-03-22 Merck Patent Gmbh Metallkomplexe
US20070219192A1 (en) 2005-11-02 2007-09-20 Xiangping Qian Certain chemical entities, compositions, and methods
WO2007056170A2 (en) 2005-11-02 2007-05-18 Bayer Healthcare Ag Pyrrolo[2,1-f] [1,2,4] triazin-4-ylamines igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases
AU2006330924B2 (en) 2005-12-21 2012-03-15 Abbvie Inc. Anti-viral compounds
TW200738709A (en) 2006-01-19 2007-10-16 Osi Pharm Inc Fused heterobicyclic kinase inhibitors
DE602007008837D1 (de) 2006-02-14 2010-10-14 Vertex Pharma Als protein-kinase-inhibitoren nutzbare dyhydrodiazepine
CN101460463A (zh) 2006-03-29 2009-06-17 先灵公司 可作为凝血酶受体拮抗剂的单环和双环喜巴辛衍生物
JP2009534454A (ja) 2006-04-25 2009-09-24 アステックス、セラピューティックス、リミテッド 医薬化合物
JP5320284B2 (ja) 2006-05-03 2013-10-23 キメリクス,インコーポレーテッド 抗ウイルス性または抗増殖性のホスホネート、ヌクレオシドホスホネートおよびヌクレオシドホスフェートの代謝安定性アルコキシアルキルエステル
WO2008001195A2 (en) 2006-06-27 2008-01-03 Glenmark Pharmaceuticals S.A. Novel processes for the preparation of dpp iv inhibitors
JP2008007634A (ja) 2006-06-29 2008-01-17 Fujifilm Corp 潤滑剤組成物
JP2009544625A (ja) 2006-07-20 2009-12-17 メーメット・カーラマン Rhoキナーゼのベンゾチオフェン阻害剤
GB0614947D0 (en) 2006-07-27 2006-09-06 Isis Innovation Epitope reduction therapy
PE20080906A1 (es) 2006-08-17 2008-07-05 Kemia Inc Derivados heteroarilo como inhibidores de citocina
WO2008024364A2 (en) 2006-08-22 2008-02-28 Redpoint Bio Corporation Heterocyclic compounds as sweetener enhancers
US20080261913A1 (en) 2006-12-28 2008-10-23 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of liver disorders
NZ598927A (en) 2007-01-12 2013-09-27 Biocryst Pharm Inc Antiviral nucleoside analogs
US20090016990A1 (en) 2007-01-24 2009-01-15 Alberte Randall S Antimicrobial Compositions
KR20100014878A (ko) 2007-01-31 2010-02-11 앨리오스 바이오파마 인크. 2-5a 유도체, 및 항암제, 항바이러스제 및 항기생충제로서 이의 용도
CA2680312A1 (en) 2007-03-07 2008-09-12 Alantos Pharmaceuticals Holding, Inc. Metalloprotease inhibitors containing a heterocyclic moiety
US8088566B2 (en) 2007-03-26 2012-01-03 Fujifilm Corporation Surface-treating agent for pattern formation and pattern-forming method using the surface-treating agent
WO2008117047A1 (en) 2007-03-27 2008-10-02 Astrazeneca Ab Pyrazolo[3, 4-d]pyrimidine derivatives as antibacterial compounds
US7956020B2 (en) 2007-03-29 2011-06-07 Fujifilm Corporation Lubricant composition, mechanical element, and method for producing triazine derivatives
US8088940B2 (en) 2007-03-30 2012-01-03 Momentive Performance Materials Inc. Hydrolyzable silanes of low VOC-generating potential and resinous compositions containing same
JP2010525063A (ja) 2007-04-27 2010-07-22 キメリクス,インコーポレイテッド ヌクレオシドホスホナートが投与された被験者における腎毒性を減少させる方法
ES2393038T3 (es) 2007-05-10 2012-12-18 Biocryst Pharmaceuticals, Inc. Compuestos de tretrahidrofuro[3,4-D]dioxolano para su utlilización en el tratamiento de las infecciones víricas y del cáncer
EP2173740A4 (en) 2007-06-14 2011-09-07 Osta Biotechnologies INHIBITORS OF HEMOXYGENASE AND THEIR USE IN THE TREATMENT OF CANCER AND DISEASES OF THE CENTRAL NERVOUS SYSTEM
US20110319459A1 (en) 2007-06-14 2011-12-29 Osta Biotechnologies Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System
GB0712494D0 (en) 2007-06-27 2007-08-08 Isis Innovation Substrate reduction therapy
CN100532388C (zh) 2007-07-16 2009-08-26 郑州大学 2’-氟-4’-取代-核苷类似物、其制备方法及应用
JP5604872B2 (ja) 2007-07-19 2014-10-15 コニカミノルタ株式会社 セルロースエステルフィルム
WO2009011228A1 (ja) 2007-07-19 2009-01-22 Konica Minolta Opto, Inc. セルロースエステルフィルム、セルロースエステルフィルムの製造方法、それを用いた偏光板、及び液晶表示装置
US9340506B2 (en) 2007-10-08 2016-05-17 Advinus Therapeutics Limited Acetamide derivatives as glucokinase activators, their process and medicinal applications
US20090318380A1 (en) 2007-11-20 2009-12-24 Pharmasset, Inc. 2',4'-substituted nucleosides as antiviral agents
AR069740A1 (es) 2007-11-29 2010-02-17 Metabasis Therapeutics Inc Compuestos nucleosidos antivirales
AU2008335031B2 (en) 2007-12-13 2013-11-28 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2009086201A1 (en) 2007-12-21 2009-07-09 Alios Biopharma, Inc. 2-5a analogs and their use as anti-cancer, anti-viral and anti- paras iti c agents
US20090176732A1 (en) 2007-12-21 2009-07-09 Alios Biopharma Inc. Protected nucleotide analogs
TW200942243A (en) 2008-03-05 2009-10-16 Biocryst Pharm Inc Antiviral therapeutic agents
EP2098226A1 (de) 2008-03-06 2009-09-09 Forschungsverbund Berlin e.V. AKAP-PKA-Interaktionshemmer zur Anwendung in der Behandlung von Herzkrankheiten
SI2937350T1 (en) 2008-04-23 2018-05-31 Gilead Sciences, Inc. 1'-SUBSTITUTED CARBON-NUCLEOUS ANALOGS FOR ANTIVIRUSAL TREATMENT
WO2010036407A2 (en) 2008-05-15 2010-04-01 Biocryst Pharmaceuticals, Inc. Antiviral nucleoside analogs
AU2009257815B2 (en) 2008-05-27 2014-05-29 Trilink Biotechnologies Chemically modified nucleoside 5'-triphosphates for thermally initiated amplification of nucleic acid
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
US7910019B2 (en) 2008-06-27 2011-03-22 Transitions Optical, Inc. Mesogen containing compounds
US7910020B2 (en) 2008-06-27 2011-03-22 Transitions Optical, Inc. Liquid crystal compositions comprising mesogen containing compounds
US8628685B2 (en) 2008-06-27 2014-01-14 Transitions Optical, Inc Mesogen-containing compounds
US7803285B2 (en) 2008-07-01 2010-09-28 Gentex Corporation Liquid crystal display device and associated liquid crystal media for use in the same
EP2313102A2 (en) 2008-07-03 2011-04-27 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents
GB0812297D0 (en) 2008-07-04 2008-08-13 Lucite Int Uk Ltd Novel carbonylation ligand sand thier use of in the carbonylation of ethylenically unsaturated compounds
UY31982A (es) 2008-07-16 2010-02-26 Boehringer Ingelheim Int Derivados de 1,2-dihidropiridin-3-carboxamidas n-sustituidas
GB0815968D0 (en) 2008-09-03 2008-10-08 Angeletti P Ist Richerche Bio Antiviral agents
JP5295692B2 (ja) 2008-09-10 2013-09-18 豊和工業株式会社 自動開閉防音サッシ
EP3587434A1 (en) 2008-09-23 2020-01-01 Alnylam Pharmaceuticals Inc. Chemical modifications of monomers and oligonucleotides with click components for conjugation with ligands
US20100096603A1 (en) 2008-10-20 2010-04-22 Nitto Denko Corporation Optical devices responsive to near infrared laser and methods of modulating light
AR074231A1 (es) 2008-11-27 2010-12-29 Boehringer Ingelheim Int Derivados de 6, 7, 8, 9-tetrahidro-5h-1, 4, 7, 10a-tetraaza-ciclohept[f]indeno, composiciones farmacéuticas que contienen estos compuestos, su uso en el agonismo del receptor 5-ht2c y procesos para prepararlos.
WO2010073126A2 (en) 2008-12-22 2010-07-01 The Governors Of The University Of Alberta Compounds useful in delivering anti-neoplastic therapy and diagnostic imaging to hypoxic cells and methods of use thereof
GB0900914D0 (en) 2009-01-20 2009-03-04 Angeletti P Ist Richerche Bio Antiviral agents
US9040718B2 (en) 2009-01-22 2015-05-26 The University Of Rochester Hybrid host materials for electrophosphorescent devices
KR20100087540A (ko) 2009-01-28 2010-08-05 삼성전자주식회사 잉크젯 기록용 잉크 조성물
EP2408306A4 (en) 2009-03-20 2012-11-07 Alios Biopharma Inc SUBSTITUTED NUCLEOSIDE AND NUCLEOTIDE ANALOGUES
US20100240604A1 (en) 2009-03-20 2010-09-23 Alios Biopharma, Inc. Protected nucleotide analogs
EP2264169A1 (en) 2009-06-15 2010-12-22 Qiagen GmbH Modified siNA
US20110212994A1 (en) 2009-06-26 2011-09-01 Brian Clem Small Molecule Choline Kinase Inhibitors, Screening Assays, and Methods for Safe and Effective Treatment of Neoplastic Disorders
WO2011005860A2 (en) 2009-07-07 2011-01-13 Alnylam Pharmaceuticals, Inc. 5' phosphate mimics
CN102473843A (zh) 2009-08-04 2012-05-23 三菱化学株式会社 光电转换元件及使用该元件的太阳能电池
EP2462138B1 (en) 2009-08-05 2014-09-24 Versitech Limited Antiviral compounds and methods of making
CN102625708A (zh) 2009-09-09 2012-08-01 阿维拉制药公司 Pi3激酶抑制剂及其用途
US20120189670A1 (en) 2009-09-14 2012-07-26 Kirkpatrick D Lynn Pharmaceutical compositions and formulations including inhibitors of the pleckstrin homology domain and methods for using same
US10023600B2 (en) 2009-09-21 2018-07-17 Gilead Sciences, Inc. Processes and intermediates for the preparation of 1′-substituted carba-nucleoside analogs
RS55699B1 (sr) 2009-09-21 2017-07-31 Gilead Sciences 2' -fluoro supstituisani karba-nukleozidni analozi zaantiviralno lečenje
US8455451B2 (en) 2009-09-21 2013-06-04 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
WO2011036557A1 (en) 2009-09-22 2011-03-31 The University Of British Columbia Compositions and methods for enhancing cellular uptake and intracellular delivery of lipid particles
WO2011038207A1 (en) 2009-09-25 2011-03-31 Metabasis Therapeutics, Inc. Phosphorus-containing thyroid hormone receptor agonists and methods of use
DE102010035730A1 (de) 2009-09-28 2011-04-07 Merck Patent Gmbh Polymerisierbare Verbindungen und ihre Verwendung in Flüssigkristallanzeigen
WO2011057214A2 (en) 2009-11-09 2011-05-12 Neurogenetic Pharmaceuticals, Inc. Gamma-secretase modulatory compounds, methods for identifying same, and uses therefor
CN102000103B (zh) 2009-12-21 2011-12-21 郑州大学 2’-氟-4’-叠氮-核苷类似物或其盐的药物应用
AR079980A1 (es) 2010-01-13 2012-03-07 Sanofi Aventis Derivados de oxazolopirimidina sustituida en 2,5,7
US9198972B2 (en) 2010-01-28 2015-12-01 Alnylam Pharmaceuticals, Inc. Monomers and oligonucleotides comprising cycloaddition adduct(s)
WO2011094890A1 (en) 2010-02-02 2011-08-11 Argusina Inc. Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
CA2791914C (en) 2010-03-05 2019-01-15 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
WO2011119869A1 (en) 2010-03-24 2011-09-29 Medical University Of South Carolina Compositions and methods for the treatment of degenerative diseases
WO2011146401A1 (en) 2010-05-17 2011-11-24 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
FR2960235B1 (fr) 2010-05-18 2013-11-01 Inst Francais Du Petrole Procede d'oligomerisation des olefines utilisant une composition comprenant un complexe organometallique contenant un ligand alcoxy fonctionnalise par un hetero-atome.
FR2960234B1 (fr) 2010-05-18 2013-11-01 Inst Francais Du Petrole Procede de dimerisation de l'ethylene en butene-1 utilisant une composition comprenant un complexe a base de titane et un ligand alcoxy fonctionnalise par un hetero-atome.
TW201201815A (en) 2010-05-28 2012-01-16 Gilead Sciences Inc 1'-substituted-carba-nucleoside prodrugs for antiviral treatment
WO2011156632A2 (en) 2010-06-09 2011-12-15 Georgetown University Compositions and methods of treatment for tumors in the nervous system
US8614021B2 (en) 2010-06-10 2013-12-24 The United States Of America As Represented By The Secretary Of The Army Agents for enhanced charge transport across microbial membranes
EP2805960A1 (en) 2010-07-19 2014-11-26 Gilead Sciences, Inc. Methods for the preparation of diasteromerically pure phosphoramidate prodrugs
SG186830A1 (en) 2010-07-22 2013-02-28 Gilead Sciences Inc Methods and compounds for treating paramyxoviridae virus infections
CN102351931B (zh) 2010-09-07 2014-01-22 河南省科学院高新技术研究中心 嘧啶核苷衍生物、合成方法及其在制备抗肿瘤、抗病毒药物中的应用
TW201305185A (zh) 2010-09-13 2013-02-01 Gilead Sciences Inc 用於抗病毒治療之2’-氟取代之碳-核苷類似物
DE102010045369A1 (de) 2010-09-14 2012-03-15 Merck Patent Gmbh Materialien für organische Elektrolumineszenzvorrichtungen
WO2012040124A1 (en) 2010-09-22 2012-03-29 Alios Biopharma, Inc. Azido nucleosides and nucleotide analogs
EA025341B1 (ru) 2010-09-22 2016-12-30 Алиос Биофарма, Инк. Замещенные аналоги нуклеотидов
US20120070411A1 (en) 2010-09-22 2012-03-22 Alios Biopharma, Inc. Substituted nucleotide analogs
WO2012068340A2 (en) 2010-11-18 2012-05-24 Opko Curna Llc Antagonat compositions and methods of use
US20150158909A1 (en) 2010-12-15 2015-06-11 Abbevie Inc. Anti-viral compounds
NZ613370A (en) 2010-12-20 2015-05-29 Gilead Sciences Inc Combinations for treating hcv
WO2012088438A1 (en) 2010-12-22 2012-06-28 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
WO2012088155A1 (en) 2010-12-22 2012-06-28 Alios Biopharma, Inc. Cyclic nucleotide analogs
WO2012092471A2 (en) 2010-12-29 2012-07-05 Development Center For Biotechnology Novel tubulin inhibitors and methods of using the same
CN103717222A (zh) 2011-02-24 2014-04-09 浙江大学 桥二硫二氧代哌嗪及其在治疗癌症方面的用途
US9370528B2 (en) 2011-03-02 2016-06-21 Volant Holdings Gmbh Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination with a hepatitis C virus infection
CN103502218B (zh) 2011-03-04 2016-08-17 生命科技公司 用于缀合生物分子的化合物和方法
BR112013023681A2 (pt) 2011-03-16 2016-12-13 Hoffmann La Roche compostos de álcool propargílico 6,5-heterocíclico e uso dos mesmos
JP2012216832A (ja) 2011-03-30 2012-11-08 Mitsubishi Chemicals Corp 光電変換素子、太陽電池、太陽電池モジュール及びインク
CA2832818A1 (en) 2011-04-06 2012-10-11 The Trustees Of Princeton University Anti-viral combination therapy
KR20130138840A (ko) 2011-04-13 2013-12-19 머크 샤프 앤드 돔 코포레이션 2''-치환된 뉴클레오시드 유도체 및 바이러스성 질환의 치료를 위한 그의 사용 방법
US8877733B2 (en) 2011-04-13 2014-11-04 Gilead Sciences, Inc. 1′-substituted pyrimidine N-nucleoside analogs for antiviral treatment
WO2012142075A1 (en) 2011-04-13 2012-10-18 Merck Sharp & Dohme Corp. 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
GB201108825D0 (en) 2011-05-25 2011-07-06 Univ Dundee Morpholino compounds, uses and methods
US20130018011A1 (en) * 2011-06-10 2013-01-17 Hassan Javanbakht Method of treating dengue fever
KR20140064765A (ko) 2011-06-30 2014-05-28 스텔라 에이피에스 Hcv 조합 치료
FR2977586B1 (fr) 2011-07-08 2013-07-12 Rhodia Operations Procede de fabrication de composes comprenant des fonctions nitriles
WO2013033270A2 (en) 2011-08-29 2013-03-07 Coferon, Inc. Bromodomain ligands capable of dimerizing in an aqueous solution, and methods of using same
BR112014005110A2 (pt) 2011-09-02 2017-04-18 Bayer Ip Gmbh pirimidinas aneladas substituídas e utilização das mesmas
CN102286047A (zh) 2011-09-14 2011-12-21 郑州大学 2’-脱氧-2’-氟-4’-三氮唑取代-β-D胞苷类似物、其制备方法及其应用
US20130072528A1 (en) 2011-09-16 2013-03-21 Abbvie Inc. Methods for Treating HCV
DE202012013074U1 (de) 2011-09-16 2014-10-29 Gilead Pharmasset Lcc Zusammensetzungen zur Behandlung von HCV
WO2013044030A1 (en) 2011-09-23 2013-03-28 Enanta Pharmaceuticals, Inc. 2'-chloroacetylenyl substituted nucleoside derivatives
MX2014004415A (es) 2011-10-14 2015-06-05 Stc Unm Bicapas lipidicas soportadas por nanoparticulas porosas (protecelulas) para suministro dirigido, incluido el suministro transdermico de carga, y los metodos relacionados.
FR2982858B1 (fr) 2011-11-18 2013-11-29 Rhodia Operations Procede de fabrication de composes comprenant des fonctions nitriles
US20130244966A1 (en) 2011-12-12 2013-09-19 Catabasis Pharmaceuticals, Inc. Fatty acid antiviral conjugates and their uses
FR2984322B1 (fr) 2011-12-16 2013-12-20 Rhodia Operations Procede de fabrication de composes comprenant des fonctions nitriles
CA2860234A1 (en) 2011-12-22 2013-06-27 Alios Biopharma, Inc. Substituted phosphorothioate nucleotide analogs
US9073960B2 (en) 2011-12-22 2015-07-07 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
EP2797594A1 (en) 2011-12-28 2014-11-05 AbbVie Inc. Methods for treating hcv
CN102603836A (zh) 2012-02-10 2012-07-25 郑州大学 五味子丙素简化物、类似物及其制备方法和应用
EA201791916A1 (ru) 2012-03-13 2018-07-31 Джилид Сайэнс, Инк. 2'-замещенные карбануклеозидные аналоги для противовирусного лечения
TWI635111B (zh) 2012-03-16 2018-09-11 馬克專利公司 共軛聚合物
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
GEP201706721B (en) 2012-03-21 2017-08-25 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
WO2013142124A1 (en) 2012-03-21 2013-09-26 Vertex Pharmaceuticals Incorporated Solid forms of a thiophosphoramidate nucleotide prodrug
WO2013142159A1 (en) 2012-03-21 2013-09-26 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
NZ630805A (en) 2012-03-22 2016-01-29 Alios Biopharma Inc Pharmaceutical combinations comprising a thionucleotide analog
WO2013147795A1 (en) 2012-03-29 2013-10-03 Empire Technology Development Llc Dioxaborinane co-polymers and uses thereof
US20150057243A1 (en) 2012-04-02 2015-02-26 Northern University Compositions and Methods for the Inhibition of Methyltransferases
JP2013237721A (ja) 2012-05-11 2013-11-28 Nitto Denko Corp 再剥離用水分散型アクリル系粘着剤組成物、及び粘着シート
EP2856531A1 (en) 2012-06-04 2015-04-08 Merck Patent GmbH Organic semiconductors
US9682970B2 (en) 2012-06-29 2017-06-20 Biotium, Inc. Fluorescent compounds and uses thereof
KR20150027155A (ko) 2012-07-03 2015-03-11 브리스톨-마이어스 스큅 컴퍼니 바이러스 감염의 치료를 위한 뉴클레오시드 화합물의 부분입체이성질체적으로 풍부한 포스포르아미데이트 유도체의 제조 방법
EP2875015A1 (en) 2012-07-23 2015-05-27 Merck Patent GmbH Ligands and their preparation
US20140038991A1 (en) 2012-08-06 2014-02-06 Astar Biotech Llc Protein Kinase Inhibitors
EP2882750A4 (en) 2012-08-10 2016-08-17 Epizyme Inc INHIBITORS OF THE PROTEIN METHYLTRANSFERASE DOT1L AND METHOD OF USE THEREOF
WO2014031872A2 (en) 2012-08-23 2014-02-27 The Broad Institute, Inc. Small molecule inhibitors for treating parasitic infections
WO2014035140A2 (en) 2012-08-30 2014-03-06 Kainos Medicine, Inc. Compounds and compositions for modulating histone methyltransferase activity
EP2712868A1 (en) 2012-09-28 2014-04-02 B. Braun Melsungen AG 5-Fluoruoracil Derivatives
MX353422B (es) 2012-10-08 2018-01-12 Idenix Pharmaceuticals Llc Análogos de 2'-cloronucleósido para infección por vhc.
DE102012109685A1 (de) 2012-10-11 2014-04-17 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verfahren zur Umwandlung reaktiver Gruppen an Si-C-gebundenen Resten von Silanen unter gleichzeitiger Vergrößerung von deren räumlichem Abstand zueinander
WO2014059901A1 (en) 2012-10-17 2014-04-24 Merck Sharp & Dohme Corp. 2'-cyano substituted nucleoside derivatives and methods of use thereof for treatment of viral diseases
WO2014059902A1 (en) 2012-10-17 2014-04-24 Merck Sharp & Dohme Corp. 2'-disubstituted substituted nucleoside derivatives and methods of use thereof for treatment of viral diseases
KR20120135501A (ko) 2012-10-29 2012-12-14 에스에프씨 주식회사 축합환 화합물 및 이를 포함한 유기 발광 소자
EP2932317B1 (en) 2012-12-14 2024-02-21 Merck Patent GmbH Birefringent rm lens
WO2014100505A1 (en) 2012-12-21 2014-06-26 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
CA2894541A1 (en) 2012-12-21 2014-06-26 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
FR2999917B1 (fr) 2012-12-26 2017-06-23 Oreal Polymere a empreinte moleculaire pour pieger selectivement les molecules odorantes
US20140200215A1 (en) 2013-01-15 2014-07-17 Intermune, Inc. Lysophosphatidic acid receptor antagonists
JP6024479B2 (ja) 2013-01-28 2016-11-16 コニカミノルタ株式会社 光学フィルム、円偏光板および画像表示装置
WO2014124458A1 (en) 2013-02-11 2014-08-14 The Regents Of The University Of California Compositions and methods for treating neurodegenerative diseases
US9580400B2 (en) 2013-02-26 2017-02-28 Northeastern University Cannabinergic nitrate esters and related analogs
US20150065439A1 (en) 2013-02-28 2015-03-05 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions
WO2014164533A1 (en) 2013-03-11 2014-10-09 Vertex Pharmaceuticals Incorporated Methods of stereoselective synthesis of substituted nucleoside analogs
US9790291B2 (en) 2013-03-14 2017-10-17 Formosa Plastics Corporation, Usa Non-phthalate compounds as electron donors for polyolefin catalysts
JP6329764B2 (ja) 2013-03-15 2018-05-23 信越化学工業株式会社 対称ハイパーブランチ型シリコーン変性重合性化合物、及びそのモジュール化した製造方法
US10138256B2 (en) 2013-03-15 2018-11-27 Celgene Car Llc MK2 inhibitors and uses thereof
CA2913206C (en) 2013-06-26 2022-08-02 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US10478445B2 (en) 2013-07-03 2019-11-19 Georgetown University Boronic acid derivatives of resveratrol for activating deacetylase enzymes
CN105473554B (zh) 2013-07-10 2019-08-13 沃泰克斯药物股份有限公司 作为离子通道调节剂的稠合的哌啶酰胺类
CN104086612A (zh) 2013-07-17 2014-10-08 郑州大学 4-取代胺基-2′-脱氧-2′-氟-4′-叠氮-β-D-胞苷类核苷化合物、制备方法及其应用
WO2015016187A1 (ja) 2013-07-29 2015-02-05 富士フイルム株式会社 非水二次電池用電解液および非水二次電池
EP3036102A4 (en) 2013-08-19 2017-01-25 Queen's University At Kingston Carbene functionalized composite materials
JP2016534124A (ja) 2013-08-29 2016-11-04 ベイラー カレッジ オブ メディスンBaylor College Of Medicine 代謝並びに体重関連疾患の処置のための組成物および方法
US10149859B2 (en) 2013-09-11 2018-12-11 Emory University Nucleotide and nucleoside therapeutic compositions and uses related thereto
US20160257657A1 (en) 2013-09-20 2016-09-08 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer
KR101628288B1 (ko) 2013-09-30 2016-06-08 주식회사 엘지화학 음성 광학 분산도를 갖는 광학 소자 제조용 조성물 및 이로부터 제조된 광학 이방체
EP3052511A4 (en) 2013-10-02 2017-05-31 Moderna Therapeutics, Inc. Polynucleotide molecules and uses thereof
TW201524990A (zh) 2013-10-11 2015-07-01 Alios Biopharma Inc 經取代之核苷、核苷酸及其類似物
CN105658219A (zh) 2013-10-25 2016-06-08 艾伯维公司 用于治疗hcv的方法
UA119050C2 (uk) 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ
US20150167017A1 (en) 2013-12-13 2015-06-18 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
CN103709220B (zh) 2014-01-13 2016-02-17 河南省科学院高新技术研究中心 3-甲基尿苷及4-甲基胞苷核苷类化合物、合成方法及其药物用途
EP2896678B1 (en) 2014-01-21 2018-10-17 Merck Patent GmbH Liquid crystal display
CN105979951B (zh) 2014-02-06 2020-12-25 里博科学有限责任公司 作为流感rna复制的抑制剂的4’-二氟甲基取代的核苷衍生物
JP6144215B2 (ja) 2014-02-07 2017-06-07 富士フイルム株式会社 光電変換素子およびその使用方法、光センサ、並びに、撮像素子
CN105960608B (zh) 2014-02-27 2018-06-15 Dic株式会社 液晶显示装置
EP2918658B1 (de) 2014-03-10 2020-05-13 Merck Patent GmbH Flüssigkristalline Medien mit homöotroper Ausrichtung
WO2015143712A1 (en) 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
JP6517319B2 (ja) 2014-03-28 2019-05-22 キャリター・サイエンシーズ・リミテッド・ライアビリティ・カンパニーCalitor Sciences, Llc 置換されたヘテロアリール化合物および使用方法
EP3131538B1 (en) 2014-04-15 2019-12-18 Nederlandse Organisatie voor toegepast- natuurwetenschappelijk onderzoek TNO New anti-clostridium compounds
US20170136132A1 (en) 2014-06-19 2017-05-18 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
WO2015196128A2 (en) 2014-06-19 2015-12-23 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
WO2015196130A2 (en) 2014-06-19 2015-12-23 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
JP5880994B1 (ja) 2014-06-23 2016-03-09 Dic株式会社 重合性液晶組成物及び該組成物を用いて作製した光学異方体、位相差膜、位相差パターニング膜
CA2952966A1 (en) 2014-06-24 2015-12-30 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
JP6669675B2 (ja) 2014-06-24 2020-03-18 ヤンセン バイオファーマ インク. 置換ヌクレオシド、ヌクレオチドおよびその類似体
KR20170081740A (ko) 2014-07-15 2017-07-12 디아이씨 가부시끼가이샤 액정 표시 장치
TWI678369B (zh) 2014-07-28 2019-12-01 美商基利科學股份有限公司 用於治療呼吸道合胞病毒感染之噻吩並[3,2-d]嘧啶、呋喃並[3,2-d]嘧啶及吡咯並[3,2-d]嘧啶化合物類
KR102289820B1 (ko) 2014-08-01 2021-08-17 삼성전자주식회사 축합환 화합물 및 이를 포함한 유기 발광 소자
US9920242B2 (en) 2014-08-22 2018-03-20 Arizona Board Of Regents On Behalf Of Arizona State University Metal-assisted delayed fluorescent materials as co-host materials for fluorescent OLEDs
EP3372655B1 (en) 2014-08-25 2019-12-18 Merck Patent GmbH Liquid-crystal medium
JP6326140B2 (ja) 2014-08-27 2018-05-16 富士フイルム株式会社 化合物、組成物、膜、光学機器
CN107108676A (zh) 2014-09-15 2017-08-29 美迪维尔公司 用于制备非对映异构纯的磷酰胺酯前药的方法
WO2016066582A1 (en) 2014-10-28 2016-05-06 Bci Pharma Nucleoside kinase inhibitors
TWI698444B (zh) * 2014-10-29 2020-07-11 美商基利科學股份有限公司 製備核糖苷的方法
CN107108683A (zh) 2014-10-31 2017-08-29 共晶制药股份有限公司 用于治疗黄病毒科病毒和癌症的2’,2’‑二卤代核苷类似物
US20170343847A1 (en) 2014-11-06 2017-11-30 Merck Patent Gmbh Light modulation element
KR20170082590A (ko) 2014-11-11 2017-07-14 메르크 파텐트 게엠베하 바이메소젠성 화합물 및 메소젠성 매질
CN105646629A (zh) 2014-11-25 2016-06-08 广州市恒诺康医药科技有限公司 L-核苷类化合物及其应用
CN105777580B (zh) 2014-12-18 2018-05-18 湖南化工研究院有限公司 酰基乙腈类化合物及其制备方法与应用
JP2018501514A (ja) 2014-12-19 2018-01-18 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung 光変調素子
MA41213A (fr) 2014-12-19 2017-10-24 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
MA41441A (fr) 2014-12-19 2017-12-12 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
EP3240859B1 (en) 2014-12-30 2018-10-24 Merck Patent GmbH Bimesogenic compounds and mesogenic media
WO2016115222A1 (en) 2015-01-14 2016-07-21 Riboscience Llc 4'-azido substituted nucleoside derivatives as inhibitors of ebola virus rna replication
EP3247767B1 (de) 2015-01-20 2018-12-26 cynora GmbH Organische moleküle, insbesondere zur verwendung in optoelektronischen bauelementen
CN107109233A (zh) 2015-01-20 2017-08-29 捷恩智株式会社 液晶组合物及液晶显示元件
EP3048159B1 (en) 2015-01-22 2019-08-07 Merck Patent GmbH Liquid crystal medium
WO2016116124A1 (en) 2015-01-23 2016-07-28 Merck Patent Gmbh Light modulation element
US20170357131A1 (en) 2015-01-23 2017-12-14 Merck Patent Gmbh Light modulation element
KR102539268B1 (ko) 2015-02-10 2023-06-07 메르크 파텐트 게엠베하 액정 매질
JP6485106B2 (ja) 2015-02-24 2019-03-20 Jnc株式会社 液晶組成物および液晶表示素子
WO2016145142A1 (en) 2015-03-10 2016-09-15 Emory University Nucleotide and nucleoside therapeutics compositions and uses related thereto
KR102587314B1 (ko) 2015-03-13 2023-10-12 메르크 파텐트 게엠베하 액정 매질
KR20160110900A (ko) 2015-03-13 2016-09-22 메르크 파텐트 게엠베하 액정 매질
JP6325171B2 (ja) 2015-03-17 2018-05-16 富士フイルム株式会社 有機半導体組成物、及び、有機半導体素子の製造方法
WO2016152340A1 (ja) 2015-03-24 2016-09-29 Jnc株式会社 液晶組成物および液晶表示素子
WO2016161176A1 (en) 2015-04-01 2016-10-06 The California Institute For Biomedical Research Methods for treating viral infections
FR3034767A1 (fr) 2015-04-07 2016-10-14 Centre Nat Rech Scient Reduction des fonctions carbonyles de glucides et derives de glucides en milieu aqueux par le dithionite de sodium
JPWO2016170948A1 (ja) 2015-04-23 2018-02-15 Jnc株式会社 液晶組成物および液晶表示素子
WO2016172631A2 (en) 2015-04-24 2016-10-27 President And Fellows Of Harvard College Substrate selective inhibitors of insulin-degrading enzyme (ide) and uses thereof
CA2984421C (en) 2015-05-01 2024-04-09 Cocrystal Pharma, Inc. Nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
CN106279322B (zh) 2015-05-15 2019-07-30 上海唐润医药科技有限公司 抗丙肝病毒的核苷类化合物及其应用
DE102015210388A1 (de) 2015-06-05 2016-12-08 Siemens Aktiengesellschaft Organische Heterozyklische Alkalimetallsalze als n-Dotierstoffe in der Organischen Elektronik
RU2018104310A (ru) 2015-07-06 2019-08-06 Байер Кропсайенс Акциенгезельшафт Азотсодержащие гетероциклы в качестве пестицидов
WO2017019817A1 (en) 2015-07-29 2017-02-02 Medivation Technologies, Inc. Methods and compositions for targeted therapeutics
WO2017019830A1 (en) 2015-07-29 2017-02-02 Medivation Technologies, Inc. Methods and compositions for targeted therapeutics
WO2017019822A1 (en) 2015-07-29 2017-02-02 Medivation Technologies, Inc. Pellet composition containing repair cells
WO2017023894A1 (en) 2015-08-03 2017-02-09 Raze Therapeutics, Inc. Mthfd2 inhibitors and uses thereof
MX2018001073A (es) 2015-08-06 2018-06-12 Chimerix Inc Nucleosidos de pirrolopirimidina y analogos de los mismos utiles como agentes antivirales.
MX2018001814A (es) 2015-08-13 2018-05-07 Merck Sharp & Dohme Compuestos dinucleotidos ciclicos como agonistas del estimulador de genes de interferon.
TW202321249A (zh) 2015-08-26 2023-06-01 比利時商健生藥品公司 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物
KR20180051582A (ko) 2015-09-09 2018-05-16 메르크 파텐트 게엠베하 액정 매질
CN106518766A (zh) 2015-09-11 2017-03-22 中国人民解放军军事医学科学院毒物药物研究所 新型二芳基脲类化合物,其制备方法及其医药用途
CN106518767A (zh) 2015-09-11 2017-03-22 中国人民解放军军事医学科学院毒物药物研究所 取代苯并吡唑二芳基脲类化合物,其制备方法及其医药用途
WO2017045740A1 (en) 2015-09-15 2017-03-23 Merck Patent Gmbh Liquid-crystalline media having homeotropic alignment
BR112018005048B8 (pt) 2015-09-16 2021-03-23 Gilead Sciences Inc uso de um composto antiviral ou sal do mesmo para o tratamento de uma infecção por coronaviridae
CN105254624B (zh) 2015-09-18 2019-08-09 上海吉铠医药科技有限公司 异噻唑衍生物pim激酶抑制剂及其制备方法与在制药中的应用
CN105218523B (zh) 2015-09-18 2019-08-23 上海吉铠医药科技有限公司 吡啶衍生物pim激酶抑制剂及其制备方法与在制药中的应用
CN105130959B (zh) 2015-09-18 2018-08-03 上海吉铠医药科技有限公司 嘧啶衍生物pim激酶抑制剂及其制备方法与在制药中的应用
EP3356347A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
WO2017059357A1 (en) 2015-09-30 2017-04-06 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of dna damaging agents and atr inhibitors
US11866754B2 (en) 2015-10-16 2024-01-09 Modernatx, Inc. Trinucleotide mRNA cap analogs
AU2016340183A1 (en) 2015-10-16 2018-04-19 Modernatx, Inc. mRNA cap analogs and methods of mRNA capping
EP4086269A1 (en) 2015-10-16 2022-11-09 ModernaTX, Inc. Mrna cap analogs with modified phosphate linkage
WO2017066791A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Sugar substituted mrna cap analogs
WO2017066782A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Hydrophobic mrna cap analogs
WO2017068875A1 (ja) 2015-10-23 2017-04-27 Jnc株式会社 液晶組成物および液晶表示素子
WO2017073932A1 (ko) 2015-10-26 2017-05-04 주식회사 엘지화학 아민 화합물 및 이를 포함하는 유기 발광 소자
WO2017073933A1 (ko) 2015-10-26 2017-05-04 주식회사 엘지화학 스피로형 화합물 및 이를 포함하는 유기 발광 소자
WO2017073931A1 (ko) 2015-10-28 2017-05-04 주식회사 엘지화학 스피로형 화합물 및 이를 포함하는 유기 발광 소자
EA201891235A1 (ru) 2015-11-25 2018-12-28 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Составы лекарственных средств для лечения злокачественной опухоли
EP3383874A1 (de) 2015-12-03 2018-10-10 Bayer CropScience Aktiengesellschaft Mesolonische halogenierte 3-(acetyl)-1-[(1,3-thiazol-5-yl)methyl]-1h-imidazo[1,2-a]pyridin-4-ium-2-olat derivate und verwandte verbindungen als insektizide
CN108368424B (zh) 2015-12-11 2022-06-03 默克专利股份有限公司 可聚合化合物及其在液晶显示器中的用途
CN106892920B (zh) 2015-12-18 2019-12-13 中国医学科学院医药生物技术研究所 苦豆碱衍生物、其制备方法及用途
KR102419178B1 (ko) 2015-12-29 2022-07-11 삼성디스플레이 주식회사 유기 발광 소자
EP3426642A4 (en) 2016-03-09 2019-10-09 Janssen BioPharma, Inc. ACYCLIC ANTIVIRALS
WO2017153186A1 (en) 2016-03-10 2017-09-14 Janssen Pharmaceutica Nv Substituted nucleoside analogues for use as prmt5 inhibitors
ES2947636T3 (es) 2016-03-16 2023-08-14 Kura Oncology Inc Derivados de tieno[2,3-d]pirimidina sustituida como inhibidores de menina-MLL y métodos de uso
WO2017165489A1 (en) 2016-03-23 2017-09-28 Emory University Antiviral agents for treating zika and dengue virus infections
CN107286190A (zh) 2016-04-13 2017-10-24 刘沛 核苷之烃氧基苄基氨基磷酸/膦酸酯衍生物的制备及其医药用途
WO2017184668A1 (en) 2016-04-20 2017-10-26 Gilead Sciences, Inc. Methods for treating flaviviridae virus infections
GB201609600D0 (en) 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
US11840766B2 (en) 2016-06-01 2023-12-12 Queen's University At Kingston Etching metal using N-heterocyclic carbenes
JP2019527381A (ja) 2016-07-20 2019-09-26 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung 光学スイッチ素子において使用するためのスイッチ層
US20190169221A1 (en) 2016-08-12 2019-06-06 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
JP2018044028A (ja) 2016-09-12 2018-03-22 オルガノサイエンス株式会社 液晶組成物
KR20230156818A (ko) 2016-10-03 2023-11-14 시질론 테라퓨틱스, 인크. 화합물, 장치, 및 이의 용도
KR20190059922A (ko) 2016-10-05 2019-05-31 메르크 파텐트 게엠베하 유기 반도체성 화합물
WO2018098206A1 (en) 2016-11-23 2018-05-31 Cv6 Therapeutics (Ni) Limited Hydantoin containing deoxyuridine triphosphatase inhibitors
WO2018106818A1 (en) 2016-12-07 2018-06-14 Kura Oncology, Inc. Methods of promoting beta cell proliferation
WO2018106820A1 (en) 2016-12-07 2018-06-14 Kura Oncology, Inc. Methods of promoting beta cell proliferation
JP6551618B2 (ja) 2016-12-16 2019-07-31 Dic株式会社 表示素子用封止材料組成物、及び、それを用いた表示素子
WO2018116901A1 (ja) 2016-12-19 2018-06-28 Dic株式会社 重合性組成物、及び、それを用いた光学異方体
WO2018119263A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds derivatives as pd-l1 internalization inducers
US11492367B2 (en) 2017-01-27 2022-11-08 Janssen Biotech, Inc. Cyclic dinucleotides as sting agonists
US12089486B2 (en) 2017-02-08 2024-09-10 Universal Display Corporation Organic electroluminescent materials and devices
AU2018235754B2 (en) * 2017-03-14 2021-04-08 Gilead Sciences, Inc. Methods of treating feline coronavirus infections
CN110691779B (zh) 2017-03-24 2023-10-10 库拉肿瘤学公司 治疗血液系统恶性肿瘤和尤因肉瘤的方法
JP2020515559A (ja) 2017-03-31 2020-05-28 ぺロトン セラピューティクス,インク. Cd73阻害剤とその使用
PL3611174T3 (pl) 2017-04-07 2022-08-08 Medshine Discovery Inc. Pochodne [1,2,4]triazolo[1,5-c]pirymidyny jako inhibitor receptora a2a
TW201902891A (zh) 2017-04-13 2019-01-16 德商麥克專利有限公司 用於有機電子裝置之組成物
ES2938859T3 (es) 2017-05-01 2023-04-17 Gilead Sciences Inc Una forma cristalina de (S)-2-etilbutilo 2-(((S)-(((2R,3S,4R,5R)-5-(4-aminopirrolo[2,1-f][1,2,4]triazin-7-il)-5-ciano-3,4-dihidroxitetrahidrofuran-2-il)metoxi)(fenoxi)fosforil)amino)propanoato
US11466047B2 (en) 2017-05-12 2022-10-11 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
US11666555B2 (en) 2017-05-17 2023-06-06 Drexel University RelA inhibitors for biofilm disruption
US10858301B2 (en) 2017-05-25 2020-12-08 The Scripps Research Institute Direct oxidation of olefins to oxygenated species
US10004719B1 (en) 2017-05-30 2018-06-26 Taigen Biotechnology Co., Ltd. Solid dispersion formulation
WO2018222172A1 (en) 2017-05-30 2018-12-06 Taigen Biotechnology Co., Ltd. Solid dispersion formulation
AU2018276305A1 (en) 2017-05-31 2019-12-19 Commonwealth Scientific And Industrial Research Organisation Inhibiting hydrocarbon hydrate agglomeration
US11542248B2 (en) 2017-06-08 2023-01-03 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
JP2018203945A (ja) 2017-06-08 2018-12-27 Dic株式会社 重合性液晶組成物、及び、それを用いた光学異方体
CN111051281A (zh) 2017-06-21 2020-04-21 波涛生命科学有限公司 用于合成的化合物、组合物和方法
CN111093627B (zh) 2017-07-11 2024-03-08 吉利德科学公司 用于治疗病毒感染的包含rna聚合酶抑制剂和环糊精的组合物
US11548893B2 (en) 2017-07-15 2023-01-10 Arisan Therapeutics Inc. Enantiomerically pure adamantane carboxamides for the treatment of filovirus infection
PL3678668T3 (pl) 2017-09-08 2024-06-03 The Board Of Trustees Of The Leland Stanford Junior University Inhibitory enpp1 i ich zastosowanie w leczeniu nowotworu
EP3681889A1 (en) 2017-09-13 2020-07-22 Merck Patent GmbH Organic semiconducting compounds
CA3075950A1 (en) 2017-09-18 2019-03-21 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
KR20190041918A (ko) 2017-10-13 2019-04-23 메르크 파텐트 게엠베하 액정 매질
US20210177827A1 (en) 2017-10-25 2021-06-17 Children`S Medical Center Corporation Papd5 inhibitors and methods of use thereof
CN111315796B (zh) 2017-11-02 2023-11-24 天光材料科技股份有限公司 有机半导体化合物
CN109748943A (zh) 2017-11-03 2019-05-14 中国科学院上海药物研究所 2’-c-甲基取代核苷类化合物及其制备与用途
CN109748944B (zh) 2017-11-03 2021-12-10 中国科学院上海药物研究所 5’-脱氧-5’-异丙基取代氨基核苷类化合物、其制备方法和用途
CN109748921B (zh) 2017-11-03 2022-03-22 中国科学院上海药物研究所 N-叔丁氧羰基保护的杂环类化合物、其制备方法及其用于制备c-核苷类似物的方法
WO2019092171A1 (en) 2017-11-09 2019-05-16 Inflazome Limited Novel sulfonamide carboxamide compounds
JP7207321B2 (ja) 2017-11-16 2023-01-18 Jsr株式会社 レジスト下層膜形成用組成物、レジスト下層膜及びその形成方法、パターニングされた基板の製造方法並びに化合物
EP3502209B1 (en) 2017-12-20 2020-10-14 Merck Patent GmbH Liquid-crystalline media having homeotropic alignment
EP3502210B1 (en) 2017-12-20 2020-09-09 Merck Patent GmbH Liquid-crystal medium
EP3727401A4 (en) 2017-12-20 2022-04-06 Merck Sharp & Dohme Corp. CYCLIC DINUCLEOTIDE COMPOUNDS USED AS STING AGONISTS
KR20190076339A (ko) 2017-12-22 2019-07-02 한미약품 주식회사 신규한 2,6-나프티리딘 2-옥시드 유도체 화합물 및 이의 용도
WO2019133712A1 (en) 2017-12-27 2019-07-04 Schinazi Raymond F Combined modalities for nucleosides and/or nadph oxidase (nox) inhibitors as myeloid-specific antiviral agents
WO2019129059A1 (zh) 2017-12-29 2019-07-04 上海和誉生物医药科技有限公司 一种具有cd73抑制活性的膦酸衍生物、其制备方法和应用
JP2019137753A (ja) 2018-02-08 2019-08-22 シャープ株式会社 液晶組成物および液晶ディスプレイ
BR112020015743A2 (pt) 2018-02-08 2020-12-15 Enyo Pharma Derivados de tiofeno não fundido e seus usos
EP3761993A4 (en) 2018-03-09 2022-03-09 Arcus Biosciences, Inc. PARENTERAL IMMUNITY-BOOSTING DRUGS
CN108276352B (zh) 2018-03-13 2022-09-20 华东理工大学 一种具有杀线虫活性的含氮杂环化合物及其制法和用途
WO2019195056A1 (en) 2018-04-04 2019-10-10 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising stem cells
WO2019215076A1 (de) 2018-05-08 2019-11-14 Bayer Aktiengesellschaft Verfahren zur herstellung stickstoffhaltiger heterocyclen
CN108727344A (zh) 2018-05-14 2018-11-02 嘉兴特科罗生物科技有限公司 一种化合物及其合成方法和应用
WO2020033413A2 (en) 2018-08-07 2020-02-13 Tosk, Inc. Modulators of ras gtpase
JP7025064B2 (ja) 2018-08-09 2022-02-24 ヤマサ醤油株式会社 4’-置換ヌクレオシド誘導体の立体選択的合成法
CN110215456A (zh) 2019-06-25 2019-09-10 华中农业大学 一种由gc376与gs-441524组成的猫冠状病毒抑制剂组合物
CN110330540A (zh) 2019-08-08 2019-10-15 木天(济南)生物科技有限公司 核苷盐及其制备方法
CN110724174B (zh) 2019-09-10 2021-02-05 广州六顺生物科技股份有限公司 吡咯并三嗪类化合物、组合物及其应用
CN110776512A (zh) 2019-11-28 2020-02-11 成都傲飞生物化学品有限责任公司 一种核苷类似物的制备方法
TWI791193B (zh) 2020-02-18 2023-02-01 美商基利科學股份有限公司 抗病毒化合物
CN118598916A (zh) 2020-02-18 2024-09-06 吉利德科学公司 抗病毒化合物
TW202245800A (zh) 2020-02-18 2022-12-01 美商基利科學股份有限公司 抗病毒化合物
CN111620909B (zh) 2020-06-05 2022-12-02 广东中科药物研究有限公司 一种瑞德西韦的前体药物及其制备方法与应用

Also Published As

Publication number Publication date
AU2021221986B2 (en) 2023-09-07
US11767337B2 (en) 2023-09-26
JP2024015041A (ja) 2024-02-01
AU2023270323A1 (en) 2023-12-14
US20240174704A1 (en) 2024-05-30
TW202143981A (zh) 2021-12-01
KR20220142483A (ko) 2022-10-21
TWI794742B (zh) 2023-03-01
CA3171497A1 (en) 2021-08-26
TW202322824A (zh) 2023-06-16
CN115087659A (zh) 2022-09-20
EP4107164A1 (en) 2022-12-28
WO2021168038A1 (en) 2021-08-26
AU2021221986A1 (en) 2022-08-18
US20210284670A1 (en) 2021-09-16
JP7483023B2 (ja) 2024-05-14
JP2023514335A (ja) 2023-04-05

Similar Documents

Publication Publication Date Title
AR121355A1 (es) Compuestos antivirales
AR121356A1 (es) Compuestos antivirales
AR091976A1 (es) Inhibidores de proteasa ns3 de vhc
AR122902A2 (es) Compuestos terapéuticamente activos y sus métodos de preparación
AR113909A1 (es) Compuestos y sus composiciones farmacéuticas para el tratamiento de hepatitis b
AR084976A1 (es) Compuestos de bifenileno sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
AR117102A1 (es) Inhibidores de arg1 y/o arg2
AR057872A1 (es) Inhibidores de la proteina activadora de 5-lipoxigenasa (flap)
AR106945A2 (es) Compuestos de isoindolina y composiciones farmacéuticas de los mismos
AR047981A1 (es) Inhibidores de caspasa y sus usos correspondientes
AR098136A1 (es) Compuestos de heteroarilo como inhibidores de btk y usos de los mismos
AR088352A1 (es) Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
AR062050A1 (es) Derivados de amina utiles como agentes anti-cancerigenos
AR102467A1 (es) Métodos para tratar infecciones por el virus filoviridae
AR088061A1 (es) Compuestos de pirazol-4-il-heterociclil-carboxamida y metodos de uso
CO6160232A2 (es) Derivados de bencimidazol
AR119010A1 (es) Compuestos, composiciones y métodos de uso
CY1113450T1 (el) Διαμινοπυριμιδινες ως ρ2χ3 και ρ2χ2/3 ανταγωνιστες
DOP2011000048A (es) Derivados de purina para usarse en el tratamiento de enfermedades alergicas, inflamatorias e infecciosas
AR094262A1 (es) Compuestos antivirales para el tratamiento de la hepatitis c
CY1116254T1 (el) Νεα 4-αμινο-4-οξοβουτανοϋλ πεπτιδια ως αναστολεις ιϊκης αντιγραφης
CO6390122A2 (es) Activadores novedosos de glucocinasa y metodos de uso de los mismos
ECSP066414A (es) Derivados de malonamida que bloquean la actividad de gama-secretasa
AR104555A1 (es) SULFONAS TRICÍCLICAS COMO MODULARES DE RORg
AR058287A1 (es) Derivados de isoquinolina y composicion farmaceutica